share_log

Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $17

Benzinga ·  Sep 27, 2024 21:15  · Ratings

Craig-Hallum analyst Alexander Nowak maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $12 to $17.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment